Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TLXBullishIndustry Newsnews

High materiality7/10

Telix advances ProstACT Global Part 2 in U.S. after FDA alignment

Jul 1, 2026, 9:33 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive regulatory alignment and clear path to US Part 2 initiation reduce execution risk and could unlock upside as the IND amendment progresses; historically, FDA protocol alignments and IND milestones for radiopharmaceuticals have driven stock moves when coupled with strong enrollment momentum.

AI summary

What happened, with direct paths to the underlying reporting

Telix announced a positive Type B FDA outcome for ProstACT Global Part 2, confirming Part 1 safety supports U.S. progression and aligning on the Part 2 protocol. The regimen comprises two TLX591-Tx doses 14 days apart with one of three SOC therapies, while an IND amendment seeks U.S. initiation and Europe remains pending. International enrollment continues, with the U.S. kickoff a near-term catalyst.

FDA Type B meeting: Part 1 safety supports US Part 2 initiation.
Part 2 uses two TLX591-Tx doses 14 days apart with SOCs.
IND amendment planned to initiate Part 2 in the U.S.; EU submission pending.
Part 2 enrollment expanding internationally; target ~490 patients.
Enrolment continues where Part 2 approved; US start timing key catalyst.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Telix advances ProstACT Global Part 2 in U.S. after FDA alignment

Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent